ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

TNF Blocking Drugs Persist in Infants after Exposure In-Utero

Anne Harding  |  May 15, 2016

NEW YORK (Reuters Health)—Babies born to mothers who took anti-tumor necrosis factor (anti-TNF) agents during pregnancy have detectable drug in their bodies up to 12 months of age, new findings show. These infants should therefore not receive live vaccines during their first year of life, Dr. Mette Julsgaard of Aarhus University Hospital in Denmark and…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabanti-TNF agentinfliximabpregnancyTNF

Rheumatology Coding Corner Question: Documentation Improvement

From the College  |  May 13, 2016

A 55-year-old female patient returns for her second infliximab infusion. Her temperature is 98°F, her height is 5’6″ and her weight is 151 lbs. She received 210 mg infliximab via infusion. The patient arrived at the clinic at 8:15 a.m. and left at 10:55 a.m. Can this encounter be coded correctly? Yes No A 38-year-old…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodingPractice Managementrheumatologistrheumatology

Biosimilars: Expanded Treatment Options

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  May 13, 2016

Soon, biosimilars will be available as treatment options for our patients. Biosimilars are being introduced to the U.S. market in the hope that they will spur competition and drive down the price of these expensive medicines. Previous articles in The Rheumatologist have touched on various issues surrounding these new therapies, and everyone in the rheumatology…

Filed under:Biologics/DMARDsDrug UpdatesPresident's Perspective Tagged with:AC&RAmerican College of Rheumatology (ACR)BiosimilarsdrugMedicationrheumatologyTreatment

Triple Therapy with Methotrexate Effective, Cheaper in RA

Larry Hand  |  April 27, 2016

NEW YORK (Reuters Health)—The combination of methotrexate, sulphasalazine and hydroxychloroquine is similar in effect as methotrexate plus biologic therapy for patients with rheumatoid arthritis (RA), according to a new network meta-analysis. “Thus, for most patients, this low-cost combination of medications should probably be tried before moving onto biologic therapy, either as initial treatment or as…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:BiologicsHYDROXYCHLOROQUINEMethotrexateRheumatoid Arthritis (RA)sulphasalazinetriple therapy

Biosimilars Debate Heats up over Cost Savings, Safety Concerns

Biosimilars Debate Heats up over Cost Savings, Safety Concerns

Susan Bernstein  |  April 15, 2016

After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

Filed under:Biologics/DMARDsDrug UpdatesLegislation & Advocacy Tagged with:BiologicsBiosimilarscost savingdebatedrugFDApatient careRheumatic DiseaserheumatologySafetyTreatment

Hidradenitis Suppurativa Can Complicate Biologic Therapy

Will Boggs, MD  |  April 13, 2016

NEW YORK (Reuters Health)—Hidradenitis suppurativa can complicate biologic therapy of chronic inflammatory diseases, according to a retrospective study from France and Belgium. Hidradenitis suppurativa (HS) often responds to treatment with biologic agents, but there have been scattered reports of patients developing HS while undergoing biologic therapy. Dr. Coline Faivre from Hôpital Edouard Herriot in Lyon,…

Filed under:Biologics/DMARDsDrug Updates Tagged with:auto-inflammatory diseasebiologic drugsBiologicsHidradenitis suppurativa

Remicade Antibodies Cross-React to Biosimilars

Lorraine L. Janeczko  |  April 6, 2016

NEW YORK (Reuters Health)—Patients with antibodies to infliximab in Remicade should not be switched to biosimilars, researchers warn. “(The) antibodies will cross-react with the new biosimilar drug, potentially reducing clinical response,” Dr. Daniel Nagore, director of research and development at Progenika Biopharma in Derio, Spain, told Reuters Health by email. “The study highlights the importance…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDAFood and Drug Administrationinfliximabinfliximab-dyyb

FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases

Reuters Staff  |  April 6, 2016

(Reuters)—The U.S. Food and Drug Administration on Tuesday approved Inflectra, a cheaper version of Johnson & Johnson’s drug Remicade (infliximab), to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine. Inflectra, also known as infliximab-dyyb, is expected by some analysts to sell for a 25% discount to Remicade, which generated annual…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsFDAFood and Drug Administrationinfliximabinfliximab-dyyb

Trying to Parse True Meaning of Pain Can be Challenging for Rheumatologists

Trying to Parse True Meaning of Pain Can Be Challenging for Rheumatologists

Simon M. Helfgott, MD  |  March 15, 2016

Discussing aching joints, sore muscles and tender limbs is all in our day’s work. We are rheumatologists; we deal in misery. But trying to parse the true meaning of these terms is among the most vexing of clinical challenges.

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:DiagnosisPainpatient carerheumatologistrheumatologyswelling

Diagnosis Can Be Elusive for Fever of Unknown Origin

Diagnosis Can Be Elusive for Fever of Unknown Origin

Charles Radis, DO  |  March 15, 2016

Settling into room 501 at Maine Medical Center, Mrs. N was on her way to the bathroom when she felt it coming on. One moment she was okay; the next, her chest felt damp and cold, even as her face flushed and her temperature spiked. Her forehead glistened beads of warm sweat. She felt the…

Filed under:Conditions Tagged with:Diagnosisfeverpatient careprodromeRheumatic DiseaseRheumatoid arthritisrheumatologistSarcoidosis

  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences